Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

Data ReadoutbempikibartNeutral

AI Analysis

Summary

Q32 Bio will report 36-week topline results from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata on July 13, 2026, with an accompanying conference call.

Clinical Trial Data

Outcome Details

36-week topline results from Part B of SIGNAL-AA clinical trial

Importance:5/10

Sentiment:

0.00

clinical_trialalopecia_areatadata_readoutconference_call

Related Companies

$QTTB

Read the original article

Published by PR Newswire Biotech on July 10, 2026 8:05 PM

Read Original